Windtree Therapeutics - About the company
Windtree Therapeutics is a public company based in Philadelphia (United States), founded in 1992. It operates as a Developer of therapies for oncology and cardiovascular diseases with unmet needs. Windtree Therapeutics has raised $45K in funding. The company has 480 active competitors, including 148 funded and 113 that have exited. Its top competitors include companies like argenx, Tenaya Therapeutics and Vor Biopharma.
Company Details
Developer of therapies for oncology and cardiovascular diseases with unmet needs. The focus is on creating treatments intended to improve current standards of care. Research programs include product candidates for chronic heart failure. These candidates include oral and intravenous SERCA2a activator heart failure compounds.
- Website
- windtreetx.com
- Social
- Email ID
- *****@windtreetx.com
Key Metrics
Founded Year
1992
Location
Philadelphia, United States
Stage
Public
Total Funding
$45K in 15 rounds
Latest Funding Round
Investors
Ranked
65th among 480 active competitors
Annual Revenue
$0 - $1M as on Dec 31, 2019
Employee Count
15 as on Jul 31, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Windtree Therapeutics
Windtree Therapeutics is associated with 3 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
DISCOVERY LABORATORIES INC /DE/ CIN: 946486 , United States, Active | $0 - $1M (As on Dec 31, 2015) | - | - | |
WINDTREE THERAPEUTICS INC /DE/ CIN: 946486 , United States, Active | Nov 05, 1992 | $0 - $1M (As on Dec 31, 2019) | - | - |
Windtree Therapeutics, Inc. CIN: 943171943 , United States, Active | Dec 31, 1999 | - | 9 (As on Dec 31, 2024) | - |
Windtree Therapeutics's IPO details
Windtree Therapeutics got listed on Aug 11, 1995.
Click here to take a look at Windtree Therapeutics's IPO in detail
Sign up to download Windtree Therapeutics' company profile
Windtree Therapeutics's funding and investors
Windtree Therapeutics has raised a total funding of $45K over 15 rounds. Windtree Therapeutics has 4 institutional investors.
Here is the list of recent funding rounds of Windtree Therapeutics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 04, 2025 | 5260229 | Post IPO | 6197526 | 5801807 | 1030128 | 3729945 |
Dec 19, 2019 | 2943915 | Post IPO | 3104852 | 8312705 | 9388618 | 3103542 |
Dec 21, 2018 | 3835206 | Post IPO | 7530302 | 6289389 | 5900282 | 6161240 |
Access funding benchmarks and valuations. Sign up today!View details of Windtree Therapeutics's funding rounds and investors
Windtree Therapeutics' founders and board of directors
Founder? Claim ProfileWindtree Therapeutics' employee count trend
Windtree Therapeutics has 15 employees as of Jul 26. Here is Windtree Therapeutics's employee count trend over the years:
Uncover Windtree Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Windtree Therapeutics's Competitors and alternates
Top competitors of Windtree Therapeutics include argenx, Tenaya Therapeutics and Vor Biopharma. Here is the list of Top 10 competitors of Windtree Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 75/100 | ||
2nd | Tenaya Therapeutics 2016, San Francisco (United States), Public | Developer of regenerative and gene therapeutics for heart failure | $248M | 70/100 | |
3rd |  Vor Biopharma 2019, Cambridge (United States), Public | Developer of therapeutics to treat acute myeloid leukemia | $152M | 68/100 | |
4th | Kiniksa Pharmaceuticals 2015, Lexington (United States), Public | Developer of therapeutics for multiple diseases treatment | $320M | 66/100 | |
5th |  Ventyx Biosciences 2018, Encinitas (United States), Acquired | Developer of therapeutics to treat autoimmune diseases | $165M | 66/100 | |
6th | Esperion Therapeutics 1998, Ann Arbor (United States), Acquired | Developer of lipoprotein cholesterol (LDL-C) lowering therapies | $107M | 66/100 | |
7th |  Structure 2017, San Francisco (United States), Public | Developer of oral small molecule drugs for chronic diseases | $191M | 65/100 | |
8th | Cellino 2017, Cambridge (United States), Series A | Developer of autologous cell therapies | $125M | 65/100 | |
9th | Radius Health 2003, Boston (United States), Acquired | Biopharmaceutical company focused on bone health and related therapeutic areas | $213M | 63/100 | |
10th | _1551769784760.png?devicePixelRatio=2&height=30&width=30){kind=logo} Rejuvenate Bio 2018, San Diego (United States), Series A | Developer of gene therapies for treating chronic and age-related diseases | $34M | 63/100 | |
65th | Windtree Therapeutics 1992, Philadelphia (United States), Public | Developer of therapies for oncology and cardiovascular diseases with unmet needs | $45K | 50/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Windtree Therapeutics's competitors? Click here to see the top ones
Windtree Therapeutics's Investments and acquisitions
Windtree Therapeutics has acquired 2 companies including CommLoan and Titan Environmental Solutions. Windtree Therapeutics has not made any investments as of now.Reports related to Windtree Therapeutics
Here is the latest report on Windtree Therapeutics's sector:
News related to Windtree Therapeutics
Filter this listMedia has covered Windtree Therapeutics for a total of 5 events in the last 1 year, 1 of them has been about company updates.
•
Windtree Therapeutics Sells Cardiovascular Biotech Pipeline Drug CandidatesBenzinga•Dec 23, 2025•Seismic, Windtree Therapeutics
•
Windtree Therapeutics to Acquire CommLoan, Inc. in Fintech ExpansionBenzinga•Dec 03, 2025•Windtree Therapeutics, CommLoan
•
Windtree Therapeutics May Receive License Agreement Payments for Renewed Acute Pulmonary DevelopmentGlobeNewswire•Nov 17, 2025•Windtree Therapeutics
•
Windtree Therapeutics to Receive $7.5M in Cash, Securities from Termination Agreement with Environmental Services CompanyGlobeNewswire•Nov 13, 2025•Tesi, Windtree Therapeutics, Titankc
•
Windtree Therapeutics issues $1.6 million in convertible notes due 2026Investing•Oct 17, 2025•Windtree Therapeutics
•
Windtree’s BNB Treasury Bet Collides With Nasdaq Delisting OrderCoinDesk•Aug 21, 2025•Windtree Therapeutics
•
Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025GlobeNewswire•Aug 11, 2025•Windtree Therapeutics
•
Nasdaq-Listed CEA Industries to Raise Up to $1.25B for BNB TreasuryBitcoin Ethereum News•Jul 29, 2025•CEA Industries, YZi Labs, 10X Capital, Windtree Therapeutics and 1 other
•
Windtree Therapeutics Reduces Preferred Shares Outstanding by Conversion and RedemptionGlobeNewswire•Jul 29, 2025•Windtree Therapeutics
•
Windtree Therapeutics Partners With Kraken To Boost BNB HoldingsTradingView•Jul 27, 2025•Windtree Therapeutics, Kraken, Binance
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Windtree Therapeutics
Explore our recently published companies
- Network Charter - Eugene based, 2003 founded, Unfunded company
- Agritech-Is - United Kingdom based, 2010 founded, Unfunded company
- King Kovers of Fremont - Fremont based, Unfunded company
- Pausetively - India based, Unfunded company
- Missy Cook - 2004 founded, Unfunded company
- Jslynch - Unfunded company
